Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma
We treated 26 eyes of 25 young patients having a mean age of 30 years with intravitreal vascular endothelial growth factor (VEGF) inhibitor for choroidal new vessel (CNV) formation overlying choroidal osteoma over a mean follow-up of 26 months. Mean number of injections was 2.4 at 6 months, 3.2 at 1...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2014/210458 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564493582860288 |
|---|---|
| author | Ahmad M. Mansour J. Fernando Arevalo Eman Al Kahtani Hernando Zegarra Emad Abboud Rajiv Anand Hamid Ahmadieh Robert A. Sisk Salman Mirza Samuray Tuncer Amparo Navea Tejerina Jorge Mataix Francisco J. Ascaso Jose S. Pulido Rainer Guthoff Winfried Goebel Young Jung Roh Alay S. Banker Ronald C. Gentile Isabel Alonso Martinez Rodney Morris Neeraj Panday Park Jung Min Emilie Mercé Timothy Y. Y. Lai Vicky Massoud Nicola G. Ghazi |
| author_facet | Ahmad M. Mansour J. Fernando Arevalo Eman Al Kahtani Hernando Zegarra Emad Abboud Rajiv Anand Hamid Ahmadieh Robert A. Sisk Salman Mirza Samuray Tuncer Amparo Navea Tejerina Jorge Mataix Francisco J. Ascaso Jose S. Pulido Rainer Guthoff Winfried Goebel Young Jung Roh Alay S. Banker Ronald C. Gentile Isabel Alonso Martinez Rodney Morris Neeraj Panday Park Jung Min Emilie Mercé Timothy Y. Y. Lai Vicky Massoud Nicola G. Ghazi |
| author_sort | Ahmad M. Mansour |
| collection | DOAJ |
| description | We treated 26 eyes of 25 young patients having a mean age of 30 years with intravitreal vascular endothelial growth factor (VEGF) inhibitor for choroidal new vessel (CNV) formation overlying choroidal osteoma over a mean follow-up of 26 months. Mean number of injections was 2.4 at 6 months, 3.2 at 12 months, and 5.5 at 24 months. CNV was subfoveal in 14 eyes, juxtafoveal in 5, extrafoveal in 5, and peripapillary in 2. By paired comparison, mean decrease from baseline was 119.7 microns at 6 months (n=15; P=0.001), 105.3 microns at 1 year (n=10; P=0.03), and 157.6 microns at 2 years (n=7; P=0.08). BCVA improved by 3.3 lines at 6 months after therapy (n=26; P<0.001), 2.8 lines (n=20; P=0.01) at 1 year, and 3.1 lines (n=13; P=0.049) at 2 years. We conclude that intravitreal anti-VEGF injections improve vision in majority of eyes with CNV from choroidal osteoma. |
| format | Article |
| id | doaj-art-a5098762174f4295a591c5e417fe7041 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-a5098762174f4295a591c5e417fe70412025-02-03T01:10:57ZengWileyJournal of Ophthalmology2090-004X2090-00582014-01-01201410.1155/2014/210458210458Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal OsteomaAhmad M. Mansour0J. Fernando Arevalo1Eman Al Kahtani2Hernando Zegarra3Emad Abboud4Rajiv Anand5Hamid Ahmadieh6Robert A. Sisk7Salman Mirza8Samuray Tuncer9Amparo Navea Tejerina10Jorge Mataix11Francisco J. Ascaso12Jose S. Pulido13Rainer Guthoff14Winfried Goebel15Young Jung Roh16Alay S. Banker17Ronald C. Gentile18Isabel Alonso Martinez19Rodney Morris20Neeraj Panday21Park Jung Min22Emilie Mercé23Timothy Y. Y. Lai24Vicky Massoud25Nicola G. Ghazi26Departments of Ophthalmology, American University of Beirut, Rafic Hariri University Hospital, P.O. Box 113-6044, Beirut, LebanonVitreoretinal Division, The King Khaled Eye Specialist Hospital, Riyadh, Saudi ArabiaVitreoretinal Division, The King Khaled Eye Specialist Hospital, Riyadh, Saudi ArabiaRetina Associates of Cleveland, 3401 Enterprise Parkway, Suite 300, Beachwood, OH 44122, USAVitreoretinal Division, The King Khaled Eye Specialist Hospital, Riyadh, Saudi ArabiaTexas Retina Associates, University of Texas Southwestern Medical Center, Dallas, TX 75231, USAOphthalmic Research Center, Shahid Beheshti University of Medical Sciences, Labbafinejad Medical Center, Tehran, IranCincinnati Eye Institute, Cincinnati, OH 45212, USABirmingham Midland Eye Centre, Dudley Road, Birmingham B187QH, UKDepartment of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Sergul Sokak Sarali Sitesi, A2 3 Gayrettepe, 34349 Istanbul, TurkeyFundación Oftalmológica del Mediterráneo, 46015 Valencia, SpainFundación Oftalmológica del Mediterráneo, 46015 Valencia, SpainDepartment of Ophthalmology, “Lozano Blesa” University Clinic Hospital, School of Medicine, University of Zaragoza, 50001 Zaragoza, SpainMayo Clinic, 200 1st Avenue South West Rochester, Minnesota, MN 55902, USAUniversity-Eye Hospital Duesseldorf, Moorenstraße 5, 40225 Duesseldorf, GermanyDepartment of Ophthalmology, University of Wuerzburg, 97080 Wuerzburg, GermanyDepartment of Ophthalmology, St. Mary’s Hospital, Catholic University of Korea, Seoul 137-701, Republic of KoreaBanker’s Retina Clinic and Laser Centre, 5 Subhash Society, Behind Ishvar Bhuvan, Ahmedabad, Gujarat 380009, IndiaDepartment of Ophthalmology, New York Eye and Ear Infirmary, New York, NY 10014, USAMartinez Center, Avenida María Guerrero 144, Leganés Norte, 28919 Madrid, SpainDepartment of Retina and Vitreous, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Avinashi Road, Coimbatore, Tamil Nadu 641014, IndiaMM Joshi Eye Institute, Gokul Road, Hosur, Hubli, Karnataka 580021, IndiaMaryknoll Medical Center, 4-12 Daecheong-dong, Jung-gu, Busan 600-730, Republic of KoreaService d’Ophtalmologie, CHU Dupuytren, 87042 Limoges, FranceDepartment of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong KongDepartments of Ophthalmology, American University of Beirut, Rafic Hariri University Hospital, P.O. Box 113-6044, Beirut, LebanonVitreoretinal Division, The King Khaled Eye Specialist Hospital, Riyadh, Saudi ArabiaWe treated 26 eyes of 25 young patients having a mean age of 30 years with intravitreal vascular endothelial growth factor (VEGF) inhibitor for choroidal new vessel (CNV) formation overlying choroidal osteoma over a mean follow-up of 26 months. Mean number of injections was 2.4 at 6 months, 3.2 at 12 months, and 5.5 at 24 months. CNV was subfoveal in 14 eyes, juxtafoveal in 5, extrafoveal in 5, and peripapillary in 2. By paired comparison, mean decrease from baseline was 119.7 microns at 6 months (n=15; P=0.001), 105.3 microns at 1 year (n=10; P=0.03), and 157.6 microns at 2 years (n=7; P=0.08). BCVA improved by 3.3 lines at 6 months after therapy (n=26; P<0.001), 2.8 lines (n=20; P=0.01) at 1 year, and 3.1 lines (n=13; P=0.049) at 2 years. We conclude that intravitreal anti-VEGF injections improve vision in majority of eyes with CNV from choroidal osteoma.http://dx.doi.org/10.1155/2014/210458 |
| spellingShingle | Ahmad M. Mansour J. Fernando Arevalo Eman Al Kahtani Hernando Zegarra Emad Abboud Rajiv Anand Hamid Ahmadieh Robert A. Sisk Salman Mirza Samuray Tuncer Amparo Navea Tejerina Jorge Mataix Francisco J. Ascaso Jose S. Pulido Rainer Guthoff Winfried Goebel Young Jung Roh Alay S. Banker Ronald C. Gentile Isabel Alonso Martinez Rodney Morris Neeraj Panday Park Jung Min Emilie Mercé Timothy Y. Y. Lai Vicky Massoud Nicola G. Ghazi Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma Journal of Ophthalmology |
| title | Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma |
| title_full | Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma |
| title_fullStr | Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma |
| title_full_unstemmed | Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma |
| title_short | Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma |
| title_sort | role of intravitreal antivascular endothelial growth factor injections for choroidal neovascularization due to choroidal osteoma |
| url | http://dx.doi.org/10.1155/2014/210458 |
| work_keys_str_mv | AT ahmadmmansour roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT jfernandoarevalo roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT emanalkahtani roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT hernandozegarra roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT emadabboud roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT rajivanand roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT hamidahmadieh roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT robertasisk roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT salmanmirza roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT samuraytuncer roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT amparonaveatejerina roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT jorgemataix roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT franciscojascaso roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT josespulido roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT rainerguthoff roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT winfriedgoebel roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT youngjungroh roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT alaysbanker roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT ronaldcgentile roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT isabelalonsomartinez roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT rodneymorris roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT neerajpanday roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT parkjungmin roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT emiliemerce roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT timothyyylai roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT vickymassoud roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma AT nicolagghazi roleofintravitrealantivascularendothelialgrowthfactorinjectionsforchoroidalneovascularizationduetochoroidalosteoma |